business:-shareholder-action-alert:-the-schall-law-firm-reminds-investors-of-a-class-action-lawsuit-against-cormedix-inc.-and-encourages-investors-with-losses-in-excess-of-$100,000-to-contact-the-firm
/ / / / / BUSINESS: SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors Of A Class Action Lawsuit Against CorMedix Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm
| | | | | |

BUSINESS: SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors Of A Class Action Lawsuit Against CorMedix Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

By Daniel Webster, dWeb.News Publisher

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CorMedix Inc. (“CorMedix” or “the Company”) (NASDAQ: CRMD) for violations of SSSS10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 16, 2019 and May 13, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before September 20, 2021.

Shareholders who have suffered a loss should contact the firm before September 2021, 2021.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.schallfirm.com, or by email at brian@schallfirm.com.

This class has not been certified yet. You are not represented until certification is granted. You can still be an absent member of the class if you do not take any action.

The Complaint alleges that the Company made misleading and false statements to the public. CorMedix was unable to manufacture DefenCath due to deficiencies. These deficiencies made it unlikely that the FDA would approve CorMedix’s NDA to DefenCath. In its public statements, the Company minimized the severity of these manufacturing issues. These facts prove that the Company’s public statements throughout the class period were false and misleading. Investors suffered losses when the market discovered the truth about CorMedix.

Register to the case and claim your losses.

The Schall Law Firm represents investors all over the globe and specializes in shareholder rights litigation and securities class action lawsuits.

The press release could be considered attorney advertising in certain jurisdictions according to the applicable law and rules.

More dWeb.News Business News at https://dweb.news/news-sections/business-news/

Similar Posts

Leave a Reply